RemeGen Submits New Indication Application for Disitamab Vedotin in Urothelial Carcinoma
CompanyDrug

RemeGen Submits New Indication Application for Disitamab Vedotin in Urothelial Carcinoma

Grand Pharma's SIR-Spheres Y-90 Gets FDA Accelerated Approval for Unresectable HCC
CompanyDrug

Grand Pharma’s SIR-Spheres Y-90 Gets FDA Accelerated Approval for Unresectable HCC

Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema
CompanyDrug

Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema

GSK Completes Acquisition of Boston Pharma's BP Asset IX for Efimosfermin Alpha
CompanyDeals

GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha

Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence
CompanyDeals

Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence

NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation
Policy / Regulatory

NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation

Roche's Chugai Pharmaceutical Partners with Gero to Develop Therapies for Age-Related Diseases
CompanyDeals

Roche’s Chugai Pharmaceutical Partners with Gero to Develop Therapies for Age-Related Diseases

CStone Pharmaceuticals Licenses Cejemly to Istituto Gentili for 23 Countries in Europe and the UK
CompanyDeals

CStone Pharmaceuticals Licenses Cejemly to Istituto Gentili for 23 Countries in Europe and the UK

Jiangsu CTTQ's TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer
CompanyDrug

Jiangsu CTTQ’s TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer

Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis
CompanyDrug

Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis

China's CDE Announces 95th Batch of Reference Preparations for Public Comment
Policy / Regulatory

China’s CDE Announces 95th Batch of Reference Preparations for Public Comment

China Ministry of Finance Restricts EU-Imported Medical Devices in Government Procurement Over RMB45 Million
Policy / Regulatory

China Ministry of Finance Restricts EU-Imported Medical Devices in Government Procurement Over RMB45 Million